Conference Proceedings

DUX study A phase 11 study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.

AJ Weickhardt, TJ Price, N Pavlakis, E Skrinos, A Dobrovic, R Salemi, AM Scott, J Mariadason, G Chong, NC Tebbutt

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2010